Urogen Pharma Ltd (URGN) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Urogen Pharma Ltd   (NASDAQ: URGN)


Urogen Pharma Ltd's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Urogen Pharma Ltd's ROI in the second quarter of 2026?
Urogen Pharma Ltd recorded a cumulative net loss of $-98 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -56.73%.

Within the Healthcare sector 511 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 3961, from total ROI ranking in the first quarter of 2026 at 4687.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -21.11 % -31.3 % -28.47 % -10.65 % 18.91 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 191 201 154 143 161
Return On Investment (TTM) -56.73 % -80.87 % -92.52 % -88.24 % -71.03 %
URGN's Overall Ranking # 3961 # 4687 # 4118 # 4051 # 3993
Seq. Investment Change TTM 4.48 % -0.7 % -11.08 % -14.48 % -9.01 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -98 -133 -153 -165 -155

URGN Company Profile >> Back to URGN Roi Comparisons >> See Annual URGN Return On Investment



Return On Investment URGN's Ranking
Within: No.
Industry # 223
Sector # 512
Overall # 3961

Return On Investment Statistics
High Average Low
-28.56 %
-80.68 %
-113.85 %
(Dec 31 2017)   (Jun 30 2022)



  News about Urogen Pharma Ltd Return on Investment ROI

UroGen Pharmas UGN-102 A Potential Breakthrough in Treating Non-Muscle Invasive Bladder Cancer

October 15, 2024

In a significant stride for both UroGen Pharma Ltd. and the realm of oncology, the company has announced the U.S. Food and Drug Administration’s (FDA) acceptance of its New Drug Application (NDA) for UGN-102, an investigational drug formulated as an intravesical solution containing mitomycin. This pivotal development presents an exciting opportunity for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (NMIBC), a condition that has long been challenging to manage.UroGen Pharma Ltd. (Nasdaq: URGN), headquartered in Princeton, N.J. has built its reputation on creating innovative solutions specifically targeting urothelial and specialty cancers. The acceptance of UGN-102’s NDA marks a pivotal moment in the company’s quest to bring forth new treatment options for patients battling NMIBC, a form of cancer that, while often manageable, still presents significant burdens to patient quality of life.





Financial Statements
Urogen Pharma Ltd's II. Quarter Investments $ 191 Millions URGN's Balance sheet
Urogen Pharma Ltd's II. Quarter Income $ -14 Millions Quarterly URGN's Income Statement
URGN's Income by Division See URGN's Income by Division


URGN Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 154 237 144 112 97
Y / Y Investment Growth -34.93 % 64.15 % 29.12 % 14.72 % -1.72 %
Net Income in Millions -153 -127 -102 -110 -111
Y / Y Net Income Growth - - - - -
Annual Return On Investment -99.65 % -53.59 % -70.89 % -98.28 % -113.82 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
URGN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for URGN's Competitors
Subscribers only: Roi for Urogen Pharma Ltd's Suppliers
Subscribers only: Return On Investment for URGN's Customers

Other Ratios
URGN's Roa URGN's Inventory Turnover Ratio URGN's Growth Rates URGN's Dividend Statistics
URGN's Profitability Ratios URGN's Asset Turnover Ratio URGN's Dividend Growth
URGN's Roe URGN's Valuation Ratios URGN's Financial Strength Ratios URGN's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-09T22:40:24+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.